Every letter we have printed

Intake relative to body mass changes during the study even when absolute intake is constant, and papers differ on which they report. The two produce different-looking results from identical data.

I asked a supplier for the shipping validation behind their stated pack and received a two-page summary with a temperature profile and a duration. It took four days. The document existed the whole time and nobody had ever requested it, which is the pattern your reporting keeps finding.

Packing configuration should be documented and almost never is. The number and placement of the coolant packs determines how long a parcel holds temperature far more than the quantity of insulation, and it varies between consignments from the same supplier.

The last mile is the part nobody controls and the part that fails. A parcel can travel refrigerated for six thousand miles and then sit in a delivery van in July for eleven hours, and the pack was specified for the journey the shipper planned rather than the one that happened.

In-use stability is where the real losses happen and where there is least data. A dry powder is forgiving; the same peptide in solution at room temperature is not. Every practical question a buyer has begins at the moment the diluent goes in, and the documentation stops at the moment before.

In-use figures quoted in this market trace back, when you follow them, to manufacturer statements about a different formulation of a different product. The chain of citation is worth publishing on its own.

You treat aggregation as a degradation pathway alongside the chemical ones. It is worth separating, because it is physical, it is often reversible in principle and irreversible in practice, and it is the one pathway that reversed-phase chromatography will not report on at all.

Of the documents I have from companies in your dossier programme, the better ones state the observed mass alongside the theoretical value and name the instrument class. That is the standard the rest of the trade could meet tomorrow, and the fact that some suppliers already meet it is the useful part of your reporting.

A mass spectrum reproduced at postage-stamp size in the corner of a certificate is decoration rather than evidence. If the document is going to carry the spectrum, it should carry it at a size where the isotope pattern is readable, or it should carry the data file reference instead.

Your piece treats the source as a fixed component. It is a consumable with a maintenance history, and a fouled source changes response for some compounds far more than others. Ask when the source was last cleaned, and you will occasionally learn more than the spectrum tells you.

Water is the invisible component nobody costs. A lyophilised cake that has taken up moisture in a warm warehouse weighs more and delivers less, and the purity figure is entirely unaffected because it is a ratio of peak areas. Two vials, same certificate, different dose.

A defence of the practice, since you have printed several attacks. Before badges existed there was no public evidence of any testing at all. The current arrangement is a poor version of a good idea and it is still an improvement on what preceded it.

I run a laboratory that issues these reports and I read your criticism as fair. What we control is the document; what happens to our logo afterwards is outside our sight entirely. We would welcome a convention that let us take it back.

The published trials in this class collected some of this data and reported very little of it, which is a genuine gap rather than a negative finding. It should be described as unreported rather than as unchanged.

Vitamin B12 status is imperfectly captured by a serum level, and the confirmatory markers are available and rarely ordered. Where the question genuinely matters, the serum value alone is the weakest form of the answer.

Rate of change is the variable most likely to modify the ratio and the one least often reported alongside it. Two studies with the same endpoint and different trajectories are not measuring the same thing.

Extrapolation beyond the study horizon is the quietest error, because it produces no obvious absurdity. A ratio observed over sixty-eight weeks says nothing about year four, and it is routinely applied to indefinite horizons.

Bone density changes lag soft tissue changes by months, so a scan taken at the end of a rapid loss period is measuring a skeleton that has not finished responding. Interpreting it as a final result is a timing error rather than a measurement one.

Pre-analytical variables account for far more surprising results than laboratory error does. Fasting state, posture during the draw, tourniquet time and the interval before separation all move numbers, and none of them appears on the report.

Tube type and fill volume matter. An underfilled tube changes the ratio of sample to additive, and the result is affected in a direction that depends on the analyte. The laboratory notices; the person receiving the report usually does not.

What a gradual reduction may do is provide a period in which habits are established while some effect remains, which is a behavioural rationale rather than a pharmacological one. Stating which kind of rationale is on offer would clarify a confused discussion.

Whatever is decided, the most useful thing anybody can do is write down the date of the last dose and what happened over the following weeks. The observational record in this area is poor mainly because nobody keeps one.

The pharmacokinetic argument for and against intermittency is at least tractable from published data, even where clinical outcomes are not. A piece that worked through the exposure arithmetic without drawing clinical conclusions would fill a real gap.

Storage does not reduce endotoxin. It is thermally stable well beyond anything a domestic process would apply, and the intuition that time or cold will help is entirely wrong here.

Your explanation of endotoxin units is the clearest I have read outside a pharmacopoeia, and the unit is where most confusion starts. A limit expressed per milligram and a limit expressed per container are different constraints, and which one applies depends on how much material is used at once.

Of the documents I have from companies in your dossier programme, the better ones state the observed mass alongside the theoretical value and name the instrument class. That is the standard the rest of the trade could meet tomorrow, and the fact that some suppliers already meet it is the useful part of your reporting.

The identity section I would accept contains four things: theoretical mass, observed mass, which mass convention was used, and the instrument. Three of the four cost nothing to print. Every certificate I hold from the wider market carries one of them.

The leucine and isoleucine problem is the cleanest illustration of your argument. They are the same mass, they are different residues, and no amount of accuracy on the intact molecule will separate them. Sequence confirmation requires fragmentation and, for that particular pair, a fragmentation method most services do not run.

Emptying rate and symptom intensity correlate poorly at the individual level, which is one of the more interesting findings in the area. It means the mechanism is necessary and not sufficient, and coverage that treats them as the same thing is misleading.

Constipation and diarrhoea both appear in the same tables and they are not the same phenomenon at all. Grouping them as gastrointestinal events obscures that motility is affected in more than one place and in more than one direction.

The placebo arm rates are substantial and almost never quoted, which makes the active arm figures look more dramatic than the comparison supports. The difference between the arms is the finding; the raw active figure is the headline.

Incidence figures from placebo-controlled trials should always be quoted with the placebo arm beside them, and in secondary coverage they almost never are. The difference between arms is the finding; the raw proportion is not.

Nobody publishes the distribution, only the proportion. Whether effects are mild across most of a population or severe in a small part of it is the question a reader has, and an incidence figure cannot answer it either way.

A protocol that permits both dose reduction and delay produces a tolerability figure describing a population that used those options. The figure is real and it is not a statement about the nominal schedule.

A note of thanks from a long-standing reader who has never written before. The consistency across thirty issues is the thing worth remarking on, and consistency never gets a letter.

Residual moisture and cake structure are set by the freeze-drying cycle, which is a manufacturing parameter nobody in this market ever asks about. It determines the stability of everything downstream of it.

Stopper choice belongs in this section. A stopper that has not been properly dried will release water into the headspace over months, and a cake that left the plant at one per cent moisture will not still be at one per cent when it arrives. The container is part of the formulation.

Dispatch day matters more than packaging. A parcel posted on a Thursday afternoon spends the weekend in a depot, and no amount of insulation is specified for that. Ask what day a shipment leaves, and if the answer is late in the week, ask them to hold it.

Agitation matters. A vial carried in a bag for a day has experienced mechanical stress that a vial on a shelf has not, and interfacial stress is a recognised cause of aggregation in protein preparations generally.

The mean kinetic temperature explanation is the clearest I have read anywhere, including in the training my employer paid for. I have printed the sidebar and put it on the wall of the dispatch room.